Shang Zhen, Zhang Qi, Liu Wanying, Wu Jiaying, Zhang Yicheng, Xiao Yi
Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Front Oncol. 2023 Oct 2;13:1242552. doi: 10.3389/fonc.2023.1242552. eCollection 2023.
ALK-negative anaplastic large cell lymphoma (ALK-ALCL) is a rare heterogeneous malignancy of T-cell origin.ALK- ALCL has a poor prognosis, with more patients experiencing relapses and refractory to treatment, and its treatment remains challenging. We report a case with bone involvement as the main clinical manifestation of recurrent, and the patient achieved significant partial remission after brentuximab vedotin(BV) combined with a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome (PLM60) with the addition of chidamide maintenance therapy and received regular follow-up, with a disease-free survival of 16 months to date. A literature review of the clinical presentation and treatment of ALCL was also conducted to identify strategies for its diagnosis and management.
ALK-ALCL with bone involvement as the main manifestation of recurrent is relatively rare. Here, BV combined a modified CHEP chemotherapy containing mitoxantrone hydrochloride liposome was applied for the first time in a patient with relapsed ALK-ALCL, inducing remission and extending survival. However, further prospective studies with many patients are needed to determine the biological characteristics of this rare type of ALK-ALCL and relevant treatment strategies.
间变性淋巴瘤激酶阴性间变性大细胞淋巴瘤（ALK阴性间变性大细胞淋巴瘤，ALK-ALCL）是一种罕见的T细胞起源的异质性恶性肿瘤。ALK-ALCL预后较差，更多患者会复发且对治疗耐药，其治疗仍然具有挑战性。我们报告1例以骨受累为主要临床表现的复发性ALK-ALCL病例，该患者在接受维布妥昔单抗（BV）联合含盐酸米托蒽醌脂质体（PLM60）的改良CHEP化疗并加用西达本胺维持治疗后获得显著部分缓解，并接受定期随访，至今无病生存16个月。我们还对ALK-ALCL的临床表现和治疗进行了文献综述，以确定其诊断和管理策略。
以骨受累为复发性主要表现的ALK-ALCL相对罕见。在此，BV联合含盐酸米托蒽醌脂质体的改良CHEP化疗首次应用于1例复发性ALK-ALCL患者，诱导缓解并延长生存期。然而，需要更多患者的进一步前瞻性研究来确定这种罕见类型ALK-ALCL的生物学特征和相关治疗策略。
